All In Biotech

Drug Trial Radar · NCT03117751

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 790 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

790

Actual

Start

Mar 29, 2017

Primary completion

Sep 30, 2026

Study completion Sep 30, 2028

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Incyte Corporation; Amgen; Servier
First posted
Apr 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). Primary Therapeutic Objectives: * To improve the event-free survival of provisional standard- or high-risk patients with genetically or immunologically targetable lesions or minimal residual disease (MRD) ≥ 5% at Day 15 or Day 22 or ≥1% at the end of Remission Induction, by the addition of molecular and immunotherapeutic approaches including tyrosine kinase inhibitors or chimeric antigen receptor (CAR) T cell / blinatumomab for refractory B-acute lymphoblastic leukemia (B-ALL) or B-lymphoblastic lymphoma (B-LLy), and the proteasome inhibitor bortezomib for those lacking targetable lesions. * To improve overall treatment outcome of T acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LLy) by optimizing pegaspargase and cyclophosphamide treatment and by the addition of new agents in patients with targetable genomic abnormalities (e.g., activated tyrosine kinases or JAK/STAT mutations) or by the addition of bortezomib for those who have a poor early response to treatment but no targetable lesions, and by administering nelarabine to T-ALL and T-LLy patients with leukemia/lymphoma cells in cerebrospinal fluid at diagnosis or MRD ≥0.01% at the end of induction. * To determine in a randomized study design whether the incidence and/or severity of acute vincristine-induced peripheral neuropathy can be reduced by decreasing the dosage of vincristine in patients with the high-risk CEP72 TT genotype or by shortening the duration of vincristine therapy in standard/high-risk patients with the CEP72 CC or CT genotype. Secondary Therapeutic Objectives: * To estimate the event-free survival and overall survival of children with ALL and to assess the non-inferiority of TOTXVII compared to the historical control given by TOTXVI. * To estimate the event-free survival and overall survival of children with LLy when ALL diagnostic and treatment approaches are used. * To evaluate the efficacy of blinatumomab in B-ALL patients with end of induction MRD ≥0.01% to \<1% and those (regardless of MRD level or TOTXVII risk category) with the genetic subtypes of BCR-ABL1, ABL-class fusion, JAK-STAT activating mutation, hypodiploid, iAMP21, ETV6-RUNX1-like, MEF2D, TCF3-HLF, or BCL2/MYC or with Down syndrome, by comparing event-free survival to historical control from TOTXVI. * To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in patients with activation of JAK-STAT signaling that can be inhibited by ruxolitinib and Day 15 or Day 22 MRD ≥5%, Day 42 MRD ≥1%, or LLy patients without complete response at the End of Induction and all patients with early T cell precursor leukemia. Biological Objectives: * To use data from clinical genomic sequencing of diagnosis, germline/remission and MRD samples to guide therapy, including incorporation of targeted agents and institution of genetic counseling and cancer surveillance. * To evaluate and implement deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing-based methods to monitor levels of MRD in bone marrow, blood, and cerebrospinal fluid. * To assess clonal diversity and evolution of pre-leukemic and leukemic populations using DNA variant detection and single-cell genomic analyses in a non-clinical, research setting. * To identify germline or somatic genomic variants associated with drug resistance of ALL cells to conventional and newer targeted anti-leukemic agents in a non-clinical, research setting. * To compare drug sensitivity of ALL cells from diagnosis to relapse in vitro and in vivo and determine if acquired resistance to specific agents is related to specific somatic genome variants that are not detected or found in only a minor clone at initial diagnosis. Supportive Care Objectives * To conduct serial neurocognitive monitoring of patients to investigate the neurocognitive trajectory, mechanisms, and risk factors. * To evaluate the impact of low-magnitude high frequency mechanical stimulation on bone mineral density and markers of bone turnover. There are several Exploratory Objectives.

Conditions

  • Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Lymphoma

Interventions

  • PrednisoneDrug

    Given orally (PO).

  • VincristineDrug

    Given intravenously (IV).

  • DaunorubicinDrug

    Given IV.

  • PegaspargaseDrug

    Given IV or intramuscularly (IM) .

  • Erwinase®Drug

    To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).

  • CyclophosphamideDrug

    Given IV.

  • CytarabineDrug

    Given IV or by subcutaneous injection (SQ).

  • MercaptopurineDrug

    Given PO.

  • DasatinibDrug

    Given PO.

  • MethotrexateDrug

    Given IV.

  • BlinatumomabDrug

    Given IV.

  • RuxolitinibDrug

    Given PO.

  • BortezomibDrug

    Given IV or subcutaneously (SQ).

  • DexamethasoneDrug

    Given PO.

  • DoxorubicinDrug

    Given IV.

  • EtoposideDrug

    Given IV.

  • ClofarabineDrug

    Given IV.

  • VorinostatDrug

    Given PO.

  • IdarubicinDrug

    Given IV.

  • NelarabineDrug

    Given IV.

  • ThioguanineDrug

    Participants with mercaptopurine-related pancreatitis. Given PO.

  • Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug

    To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).

  • Calaspargase PegolDrug

    To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival of ALL patients (EFS)Time frame: At 3.5 years after enrollment of the last participant
  2. Proportion of patients with CEP72TT genotype who develop two or more episodes of Grade 2 or higher neuropathy during ContinuationTime frame: At 6 months after the last randomized patient completes Continuation Treatment (Week 120).
  3. Cumulative incidence of Grade 2 or higher neuropathy in patients with CEP72 CC or CT genotypeTime frame: After the last randomized patient is followed for 1 year after Week 101 of Continuation therapy

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • Rady Children's Hospital San Diego

    San Diego, California

  • Children's Hospital of Illinois at OSF-Saint Francis Medical Center (St. Jude Midwest Affiliate - Peoria)

    Peoria, Illinois

  • Children's Hospital of Michigan

    Detroit, Michigan

  • St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital

    Charlotte, North Carolina

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

  • The Royal Children's Hospital Melbourne

    Parkville, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.